Do you want to join us?
We are a dynamic team of passionate professionals advancing the frontier of antibody therapeuticsSee open positions here
Servier presents its 2020/21 annual results, its R&D strategy and pipeline
January 2022Read more
Meet a colleague
Click here to meet some of our colleagues and learn about their roles and storiesRead more
We advance superior mAb therapeutics to improve the lives of cancer patients
Symphogen is the Antibody Center of Excellence in the Servier Group. We are primarily focused on oncology and immune oncology. We have a highly efficient antibody discovery and research platform supported by comprehensive early development capabilities.
Our antibody platform delivers antibodies with unique functionalities providing best or first in class potential as combination or mono therapy. Our approach and capabilities are well suited for combination therapies at the core of future cancer treatment.